Lipella reports positive phase 2a results from second lp-310 cohort in oral lichen planus; final data expected q2 2025

Listen: pittsburgh, april 22, 2025 – prism mediawire – lipella pharmaceuticals inc. (nasdaq: lipo) (“lipella,” “our,” “us,” or the “company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today announced positive topline results from the second cohort (0.
LIPO Ratings Summary
LIPO Quant Ranking